- Record: found
- Abstract: not found
- Article: not found
Experience with sorafenib and adverse event management
April 2011
April 2011
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Abstract
Sorafenib was the first multikinase inhibitor to be approved for use in renal cell
cancer (RCC) in the US (2005) and in Europe (2006). In the Treatment Approaches in
Renal Cell Cancer Global Evaluation Trial (TARGET), sorafenib showed a significant
progression-free survival advantage over placebo in patients with advanced RCC. Incidence
rates of adverse events were significantly higher with sorafenib than with placebo.
Management of adverse events is an essential component of care to prevent negative
impact on patient quality of life and dose modification of sorafenib therapy. This
report, based on an expert panel discussion held in February 2009, presents recommendations
for the management of skin rash, hand-foot skin reaction, diarrhea, and hypertension,
and strategies to help lessen the frequency and severity of these events. In addition,
general recommendations for dose modifications are discussed. The goal of these management
recommendations is to optimize sorafenib therapy for advanced RCC.
Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.